Latest Glucose Stories
It has long been known that cancer cells use nutrients differently than normal cells.
PositiveID Corporation (OTCBB: PSID) the parent company of the iglucoseâ„¢ system is bringing the future technology of diabeties management to consumers now has created a comprehensive video presentation
The condition tuberous sclerosis, due to mutation in one of two tumor suppressor genes, TSC1 or TSC2, causes the growth of non-malignant tumors throughout the body and skin.
Scientists may someday be able to develop therapies that target this pathway to treat or prevent a variety of diseases, including diabetes as reported by DiabeticLive.com. Orlando,
PositiveID Corporation (OTCBB: PSID), the parent company of the iglucoseâ„¢ system, is bringing the future technology of diabetes management to consumers now.
Paul Spivak invents another revolutionary product. Mentor, Ohio (PRWEB) October 07, 2011 According to company president, Paul Spivak, this patented scientific
What do you know; two culprits turn out to be related! Cancer and diabetes appear to have some biology in common. A pathway that initially drew attention for its role in embryonic stem cells and cancer also influences the odds that mice develop or resist diabetes.
Contrary to what you might think, cancer and diabetes appear to have some biology in common.
Researchers at the John G. Rangos Sr. Research Center at Children's Hospital of Pittsburgh of UPMC and the University of Pittsburgh School of Medicine have identified a powerful molecular pathway that regulates the liver's management of insulin and new glucose production, which could lead to new therapies for diabetes.
If the brain goes hungry, Twinkies look a lot better.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.
More Images (2 images) »